mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model
Ellen King, Chayanika Saha, Rabia Saleem, Binyumeng Jiang, Eve O’Donoghue, Federica Cottone, Helen O McCarthy, Olga Piskareva · 2026
Read mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model by Ellen King, Chayanika Saha, Rabia Saleem, Binyumeng Jiang, Eve O’Donoghue, Federica Cottone, Helen O McCarthy, Olga Piskareva (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13293994.txt.
Description
Ellen King leads a 2026 mouse study of the first messenger RNA vaccine aimed at neuroblastoma, a childhood tumor behind 15% of pediatric cancer deaths. The vaccine uses self-assembling RALA peptides to carry RNA coding for glypican 2, a surface protein common on these tumors. Lab checks confirmed particle form, cell uptake, and function before animal dosing.
Vaccinated mice mounted a GPC2-specific cell response, with higher IFN-γ and IL-2 signals and stronger TNF-α from helper and killer T cells. In a MYCN-amplified tumor model, growth was delayed by 10–11 days and volume cut by 70% versus controls. Glypican 2 also rises in other cancers.
Catalog record
| CREATOR | Ellen King, Chayanika Saha, Rabia Saleem, Binyumeng Jiang, Eve O’Donoghue, Federica Cottone, Helen O McCarthy, Olga Piskareva |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50564 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |